scholarly journals Benefit of Ginkgo biloba for Dementia

2021 ◽  
Vol 3 (1) ◽  
pp. 125-128
Author(s):  
Citra Ananta Avis
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Cognitive Processes ◽  
Ginkgo Biloba ◽  
Good Effect ◽  
Pharmacological Management ◽  
The Family ◽  
The Brain

Dementia is a chronic progressive brain illness syndrome defined by the loss of numerous cognitive processes, including memory, aphasia, apraxia, agnosia, and executive function. Consciousness is usually unaffected. Psychological and behaviour issues are sometimes present. Dementia is caused by a number of diseases and accidents that affect the brain, either directly or indirectly, such as Alzheimer's disease or stroke. Vascular dementia is a loss of thinking capacity caused by disorders that impede blood flow to certain parts of the brain, depriving brain cells of oxygen and nutrients. After Alzheimer's disease, vascular dementia is the second most frequent kind of dementia. This case study looks at a 76-year-old woman who has vascular dementia. The goal of pharmacological management with risperidone in low dose, as well as psychotherapy, in patients is to preserve and maximize function, reduce behaviour problems, relieve caregiver stress, and delay advancement to the next level. Ginkgo Biloba is one of the plants classified as phytopharmacology or medicines derived from of the plant is Ginkgo biloba Plant G. biloba (Gb) is included in the family Ginkgoaceae. In the G. biloba extract has antioxidant, antiviral, anti-inflammatory, and anti-carcinogenic properties. And also have it was stated that G. biloba extract had a good effect on the function of the CNS (central nervous system).

SPECIFIC PROPERTIES OF TUBULIN IN THE PREFRONTAL CORTEX IN CONTROL, SCHIZOPHRENIA AND VASCULAR DEMENTIA

2020 ◽  
pp. 65-71
Author(s):  
Burbaeva G.Sh. ◽  
Androsova L.V. ◽  
Vorobyeva E.A. ◽  
Savushkina O.K.
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prefrontal Cortex ◽  
Vascular Dementia ◽  
Binding Activity ◽  
Nephelometric Method ◽  
Rate Of Polymerization ◽  
Mental Diseases ◽  
And Control ◽  
The Brain

The aim of the study was to evaluate the rate of polymerization of tubulin into microtubules and determine the level of colchicine binding (colchicine-binding activity of tubulin) in the prefrontal cortex in schizophrenia, vascular dementia (VD) and control. Colchicine-binding activity of tubulin was determined by Sherlinе in tubulin-enriched extracts of proteins from the samples. Measurement of light scattering during the polymerization of the tubulin was carried out using the nephelometric method at a wavelength of 450-550 nm. There was a significant decrease in colchicine-binding activity and the rate of tubulin polymerization in the prefrontal cortex in both diseases, and in VD to a greater extent than in schizophrenia. The obtained results suggest that not only in Alzheimer's disease, but also in other mental diseases such as schizophrenia and VD, there is a decrease in the level of tubulin in the prefrontal cortex of the brain, although to a lesser extent than in Alzheimer's disease, and consequently the amount of microtubules.

Lipidomics and cognitive dysfunction – A Narrative review

2020 ◽  
Vol 45 (2) ◽  
Author(s):  
Arpita Chakraborty ◽  
Samir Kumar Praharaj ◽  
R. V. Krishnananda Prabhu ◽  
M. Mukhyaprana Prabhu
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Vascular Dementia ◽  
Cognitive Dysfunction ◽  
Neurological Disorders ◽  
Brain Lipids ◽  
Complex Lipids ◽  
Functional Components ◽  
The Brain

AbstractBackgroundMore than half portion of the brain is formed by lipids. They play critical roles in maintaining the brain's structural and functional components. Any dysregulation in these brain lipids can lead to cognitive dysfunction which are associated with neurological disorders such as Alzheimer's disease, Parkinson's disease, schizophrenia, vascular dementia etc. Studies have linked lipids with cognitive impairment. But not much has been studied about the complex brain lipids which might play a pivotal role in cognitive impairment. This review aims to highlight the lipidomic profiles in patients with cognitive dysfunction.ResultsForty-five articles were reviewed. These studies show alterations in complex lipids such as sphingolipids, phospholipids, glycolipids and sterols in brain in various neurological disorders such as vascular dementia, Parkinson's and Alzheimer's disease. However, the classes of fatty acids in these lipids involved are different across studies.ConclusionsThere is a need for targeted lipidomics analysis, specifically including sphingolipids in patients with neurodegenerative disorders so as to improve diagnostics as well as management of these disorders.

Alzheimer’s disease and its related Dementia types: A review on their management via nanotechnology based therapeutic strategies

2021 ◽  
Vol 18 ◽  
Author(s):  
Panoraia I. Siafaka ◽  
Gökce Mutlu ◽  
Neslihan Üstündağ Okur
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
The Body ◽  
Daily Routine ◽  
Mixed Dementia ◽  
The Brain

Background: Dementia and its related types such as Alzheimer’s disease, vascular dementia and mixed dementia belong to brain associated diseases, resulting in long-term progressive memory loss. These diseases are so severe that can affect a person's daily routine. Up to date, treatment of de- mentias is still an unmet challenge due to their complex pathophysiology and unavailable efficient pharmacological approaches. The use of nanotechnology based pharmaceutical products could possibly improve the management of dementia given that nanocarriers could more efficiently deliver drugs to the brain. Objective: The objective of this study is to provide the current nanotechnology based drug delivery systems for the treatment of various dementia types. In addition, the current diagnosis biomarkers for the mentioned dementia types along with their available pharmacological treatment are being dis- cussed. Method: An extensive review of the current nanosystems such as brain drug delivery systems against Alzheimer’s disease, vascular dementia and mixed dementia was performed. Moreover, nan- otheranostics as possible imaging markers for such dementias were also reported. Results: The field of nanotechnology is quite advantageous for targeting dementia given that nanoscale drug delivery systems easily penetrate the blood brain barrier and circulate in the body for prolonged time. These nanoformulations consist of polymeric nanoparticles, solid lipid nanoparticles, nanostruc- tured lipid carriers, microemulsions, nanoemulsions, and liquid crystals. The delivery of the nan- otherapeutics can be achieved via various administration routes such as transdermal, injectable, oral, and more importantly, through the intranasal route. Nonetheless, the nanocarriers are mostly limited to Alzheimer’s disease targeting; thus, nanocarriers for other types of dementia should be developed. Conclusion: To conclude, understanding the mechanism of neurodegeneration and reviewing the cur- rent drug delivery systems for Alzheimer’s disease and other dementia types are significant for medical and pharmaceutical society to produce efficient therapeutic choices and novel strategies based on mul- tifunctional and biocompatible nanocarriers, which can deliver the drug sufficiently into the brain.

Apraxic and Action-Intentional Disorders Associated With Vascular and Degenerative Dementing Diseases

2020 ◽  
pp. 146-184
Author(s):  
Kenneth M. Heilman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Working Memory ◽  
Episodic Memory ◽  
Executive Functions ◽  
Vascular Dementia ◽  
Response Inhibition ◽  
Word Fluency ◽  
Letter Word ◽  
The Brain

“Actions speak louder than words.” Although clinician’s behavioral evaluations of dementia most often include assessing episodic memory, declarative memories (e.g., naming and calculating), and executive functions (working memory, letter–word fluency), one of the most important functions of the brain is programing actions, including “how” to move and “when” to move. Patients with Alzheimer’s disease, vascular dementia, and other forms of dementia often have impairments in the systems that mediate these how-apraxic and when-intentional behaviors. Although the presence of these apraxic and action-intentional disorders may help with diagnosis and help doctors gain a better understand these patients’ disability, these functions are rarely tested and are often not well understood. The goal of this chapter is to describe the signs of the various types of apraxic disorders (limb-kinetic, ideomotor, conceptual, ideational, and dissociation) and well as action-intentional disorders (akinesia-hypokinesia, impersistence, perseveration, and defective response inhibition), how to test for these disorders, and their pathophysiology.

Neuropathology of Alzheimer’s Disease and Vascular Dementia

2020 ◽  
pp. 333-374
Author(s):  
Alifiya Kapasi ◽  
Julia A. Schneider
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Vascular Dementia ◽  
Cerebral Injury ◽  
Community Based ◽  
Neuropsychological Examination ◽  
Vessel Disease ◽  
Pathological Characteristics ◽  
Diagnosis Of Dementia ◽  
The Brain

There are numerous distinct brain pathologies that underlie a clinical diagnosis of dementia. This chapter focuses on the two most common and well-recognized brain pathologies associated with dementia, Alzheimer’s disease and vascular dementia. The authors describe the distinguishing pathological characteristics of Alzheimer’s disease, followed by the pathological hallmarks of vascular dementia including the characteristics of vessel disease and cerebrovascular tissue injuries. The chapter highlights the importance of mixed or co-morbid Alzheimer’s disease and vascular cerebral injury that has been described in multiple clinical pathologic studies, especially in community-based studies. Finally, the authors discuss how data obtained from both clinical and neuropsychological examination of the brain can be integrated.

Longitudinal Changes in Individual BrainAGE in Healthy Aging, Mild Cognitive Impairment, and Alzheimer’s Disease

GeroPsych ◽  
2012 ◽  
Vol 25 (4) ◽  
pp. 235-245 ◽  
Author(s):  
Katja Franke ◽  
Christian Gaser
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Healthy Aging ◽  
Brain Aging ◽  
Elderly Subjects ◽  
Additional Increase ◽  
Longitudinal Changes ◽  
Novel Method ◽  
The Brain

We recently proposed a novel method that aggregates the multidimensional aging pattern across the brain to a single value. This method proved to provide stable and reliable estimates of brain aging – even across different scanners. While investigating longitudinal changes in BrainAGE in about 400 elderly subjects, we discovered that patients with Alzheimer’s disease and subjects who had converted to AD within 3 years showed accelerated brain atrophy by +6 years at baseline. An additional increase in BrainAGE accumulated to a score of about +9 years during follow-up. Accelerated brain aging was related to prospective cognitive decline and disease severity. In conclusion, the BrainAGE framework indicates discrepancies in brain aging and could thus serve as an indicator for cognitive functioning in the future.

The Weak Combined Magnetic Fields Reduce the Brain β-Amyloid in an Animal Model of Sporadic Alzheimer's Disease

PIERS Online ◽  
2009 ◽  
Vol 5 (4) ◽  
pp. 311-315 ◽  
Author(s):  
Natalia V. Bobkova ◽  
Vadim V. Novikov ◽  
Natalia I. Medvinskaya ◽  
Irina Yu. Aleksandrova ◽  
Eugenii E. Fesenko
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Animal Model ◽  
Magnetic Fields ◽  
Sporadic Alzheimer’S Disease ◽  
Combined Magnetic Fields ◽  
The Brain
Sign in / Sign up

Export Citation Format

Share Document